Viability of pancreatic cancer cell lines with different KRAS mutational status, namely MiaPaCa (KRAS G12C), Panc-1 (KRAS G12D), and BxPC3 (KRAS wild-type), was analyzed using Celltiter-Glo luminescent assay, which relies on the quantitation of ATP present in the cells as the measure of metabolically active cells. This evidence concerns the gene KRAS and familial pancreatic carcinoma.